Q4 2024 Earnings Summary
- Philip Morris International (PM) expects continued and potentially accelerating growth in its heated tobacco unit (HTU) volumes, driven by organic growth in existing markets and potential expansion into new geographies. The company notes that approximately 20% of their heat-not-burn volume's full growth potential is currently unrealized due to constraints in Russia and Ukraine, and as these markets normalize, they anticipate additional growth beyond 2025 .
- PM anticipates robust margin expansion in 2025, supported by positive product mix shifts towards higher-margin smoke-free products, successful pricing strategies, and cost efficiencies. The growth of ZYN in the U.S.—described as "best-in-class" in terms of margin—is a significant contributor . The company is targeting "nice margin improvement, both organically and in dollar terms for '25", aided by easing cost headwinds and economies of scale .
- PM is confident about obtaining regulatory authorization for IQOS ILUMA in the U.S. around mid-2025, which would open a substantial new market for the company . They believe that IQOS could become a net contributor to the bottom line in the U.S. within 2 to 3 years, given the product's strong international performance and the lack of cannibalization risk in the U.S. market .
- Implementation of flavor bans in key European markets like Italy and potentially Poland is leading to softer-than-expected performance in smoke-free products. In Italy, the second half was a bit weaker than expected due to smokers reverting back to cigarettes or switching to e-vapor products, impacting overall growth. The impact in Poland is uncertain but may occur in 2025.
- Increased competition in the U.S. nicotine pouch market from competitors launching synthetic moist nicotine products may challenge ZYN's market share and growth trajectory. While current impact is minimal, these products could appeal to moist snuff users and pose a threat to ZYN's dominance in the dry pouch segment.
- Potential delays in IQOS ILUMA's profitability in the U.S., with initial investments expected to negatively impact margins in the near term. It may take 2 to 3 years for IQOS to become a net contributor to the bottom line, which could weigh on overall company profitability during this period.
| Metric | YoY Change | Reason |
|---|---|---|
Total Revenue | +7% | Favorable pricing in both combustible and smoke-free products offset volume softness. Higher smoke-free adoption also contributed to organic growth. |
Operating Income (EBIT) | +13% | Pricing gains and cost controls improved margins. Expense-related one-offs in the previous year provided a favorable comparison, further boosting EBIT. |
Net Income | −126% | Significant special charges and possible impairments drove net income negative compared to last year. Rising interest expenses and higher tax provisions also weighed on results. |
EPS (Diluted) | −127% | Mirrors the drop in net income. One-time charges and increased financing costs sharply reduced earnings per share year-over-year. |
Combustible Tobacco | +6% | Price hikes in key markets offset partial volume declines. Although input costs rose, the segment remains critical for cash flow. |
Smoke-Free Products | +9% | Continued IQOS expansion and ZYN uptake fueled revenue growth. A wider consumer shift toward reduced-risk products also supported the increase. |
Europe Revenue | +12% | Higher HTU volumes and robust pricing in combustible products drove gains. Market share improvements and currency tailwinds contributed positively. |
SSEA, CIS & MEA Revenue | +6% | Pricing improvements in combustible tobacco and increased HTU adoption offset inflationary cost pressures. Ongoing shift toward smoke-free formats also supported growth. |
Americas Revenue | +131% | Reflects rapid nicotine pouch expansion in the U.S. and stronger pricing. A comparatively lower revenue base in the prior period amplified the year-over-year jump. |
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Total Volume Growth | FY 2025 | no prior guidance | Up to +2% | no prior guidance |
Smoke-Free Products Volume Growth | FY 2025 | no prior guidance | +12% to +14% | no prior guidance |
HTU Adjusted IMS Growth | FY 2025 | no prior guidance | +12% to +14% | no prior guidance |
HTU Shipment Volume | FY 2025 | no prior guidance | Expected to align with the double-digit IMS growth trajectory | no prior guidance |
ZYN U.S. Shipment Volume | FY 2025 | no prior guidance | 780 million to 820 million cans | no prior guidance |
Organic Net Revenue Growth | FY 2025 | no prior guidance | +6% to +8% | no prior guidance |
Adjusted Operating Income Growth | FY 2025 | no prior guidance | +10.5% to +12.5% | no prior guidance |
Adjusted Diluted EPS Growth (Currency-Neutral) | FY 2025 | no prior guidance | +10.5% to +12.5% | no prior guidance |
Adjusted Diluted EPS Growth (Dollar Terms) | FY 2025 | no prior guidance | +7% to +9% ($7.40 to $7.70) | no prior guidance |
Gross Profit and Operating Margin | FY 2025 | no prior guidance | Both are expected to expand | no prior guidance |
Corporate Tax Rate | FY 2025 | no prior guidance | 22.5% to 23.5% | no prior guidance |
Operating Cash Flow | FY 2025 | no prior guidance | ~$11 billion | no prior guidance |
Capital Expenditure | FY 2025 | no prior guidance | ~$1.5 billion | no prior guidance |
Net Debt to Adjusted EBITDA Ratio | FY 2025 | no prior guidance | ~2x by the end of 2026 | no prior guidance |
HTU Adjusted IMS Growth | Q1 2025 | no prior guidance | +10% | no prior guidance |
HTU Shipment Volume | Q1 2025 | no prior guidance | 35 billion to 36 billion units | no prior guidance |
ZYN Shipment Volume | Q1 2025 | no prior guidance | 170 million to 180 million cans | no prior guidance |
Adjusted Diluted EPS | Q1 2025 | no prior guidance | $1.58 to $1.63 | no prior guidance |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Strong Pricing Power | Cited in Q1, Q2, Q3 as a key driver, with increases of 5.5% to ~9% in combustibles and ~2–3% in smoke-free products . | Maintains ~8.7% full-year growth in combustibles and ~2% in smoke-free in Q4 . | Remains a major bullish factor with consistent gains across quarters . |
IQOS & Heated Tobacco Expansion | Q1–Q3 showed ~11–14% volume growth and multiple new markets (e.g., Indonesia, Mexico), with strong uptake in Japan and Europe . | Q4 sees ~13% volume growth, continued expansion in Europe, Japan, and select emerging markets . | Consistently bullish, volume and geography continue to expand . |
IQOS ILUMA U.S. Approval | Q2 and Q3 indicated possible H2 2025 FDA authorization, with pilot programs in Texas but no immediate volumes . | Q4 emphasizes a mid-2025 FDA decision, near-term margin pressure, and potential profitability within 2–3 years. | New Q4 focus on approval timeline and profitability path . |
Flavor Bans in Europe | Mentioned in Q1–Q3 as causing short-term disruptions in Italy and other EU markets but showing partial recovery . | Q4 highlights ~1 billion unit impact expected in 2025; long-term stabilization foreseen . | Ongoing headwind but recovery continues; still affects smoke-free volumes . |
Competition in U.S. Nicotine Pouches | Q2 and Q3 flagged increasing synthetic and unauthorized pouch products; focus on regulatory enforcement . | Q4 notes limited traction of synthetic moist pouches; minimal market share shift. | Persistent concern but impact remains small . |
IQOS Profitability in U.S. | Not a prominent topic in Q1–Q3 (no direct updates on short-term vs. long-term margins) [—]. | Q4 underscores a positive long-term outlook, with near-term margin pressure due to launch costs. | Newly discussed in Q4, highlighting bullish long-term potential. |
Cost Efficiencies & Margin Expansion | Q1–Q3 saw emphasis on ~$2–3B cost savings across COGS/SG&A, with organic margin gains (150–330 bps) . | Q4 achieved ~$750M gross efficiencies and +330 bps margin expansion, viewing 2025 as a key milestone . | Consistently positive, supporting stronger margins into 2025 . |
VEEV Profitability Path | Q1 projected H2 2024 profitability; Q2 mentioned it briefly, Q3 gave almost no update . | No direct update in Q4 [—]. | Reduced discussion after Q1; not covered in latest call . |
Currency Headwinds | Q1 showed persistent concern (e.g., $0.20 EPS hit); Q2–Q3 discussed mitigating tactics and declining emphasis . | In Q4, some ongoing impact (e.g., ~$0.22 in 2025) but largely offset by pricing and hedging . | Diminished emphasis versus Q1, still monitored but less critical . |
Legal & Regulatory Focus | Q2 mentioned a D.C. subpoena, Q3 covered a Canadian settlement with uncertain tax treatment . | No direct mention in Q4 [—]. | Not discussed most recently; earlier quarters had more detail . |
-
Margin Expansion Outlook
Q: What are the key drivers behind your margin expansion guidance?
A: We expect robust margin expansion in 2025, driven by pricing contributions, a favorable product mix with higher-margin smoke-free products like ZYN and IQOS, and easing cost pressures. Productivity improvements and economies of scale, particularly in device sales, will also contribute. We anticipate this will widen the margin gap between smoke-free products and combustibles, extending beyond the current 10 percentage point difference. (Citations: , ) -
ZYN Growth and Supply Normalization
Q: How confident are you in achieving your 34–41% ZYN volume growth guidance given current supply constraints?
A: Despite mid-teens growth indicated by scanner data due to supply limitations, we're confident in achieving our 34–41% growth guidance. We've observed increasing velocities in Q4 and significant sequential growth with our increased capacity in Owensboro. The recent FDA authorization of all ZYN variants enhances market visibility and, coupled with full supply normalization by mid-2025, supports our growth projections. (Citations: ) -
HTU Growth Acceleration in 2026
Q: What gives you confidence in an acceleration of HTU growth in 2026?
A: While our 2025 guidance focuses on organic growth in existing markets, we anticipate new geographies opening up in 2026, which haven't been included in current projections. Additionally, we're not fully realizing growth potential in markets like Russia and Ukraine. Combined with our multi-category strategy and continued user acquisitions, we expect accelerated growth in total smoke-free volumes. (Citations: ) -
Impact of Flavor Bans in Europe
Q: How are flavor bans in Italy and Poland affecting your business?
A: The flavor ban in Italy led to a softer Q4, with some users temporarily returning to cigarettes, impacting growth. We expect recovery as the smoke-free category stabilizes and our multi-category strategy addresses user needs. In Poland, the flavor ban is anticipated to be implemented toward the end of 2025, and we're closely monitoring its potential impact on the European combustibles business. (Citations: ) -
ILUMA Entry into the U.S. Market
Q: Does your guidance assume entry of ILUMA in the U.S., and how will it impact margins?
A: We anticipate receiving FDA authorization for IQOS around mid-year. While initial investments in ILUMA will negatively impact margins, we expect IQOS to become a net contributor to the bottom line in 2–3 years, mirroring patterns observed in other markets. Our guidance includes potential investments but not corresponding sales from ILUMA U.S. entry. (Citations: ) -
Competition from Moist Nicotine Products
Q: How do you view the competition from moist nicotine products in the U.S.?
A: Although competitors have launched synthetic moist nicotine products showing initial upticks, they account for a market shift of just 20 basis points year-over-year. Moist products tend to attract moist snuff users, while our dry product, ZYN, appeals more to smokers and e-vapers. We do not see significant traction that would impact our growth trajectory. (Citations: ) -
Foreign Exchange Headwinds and Hedging
Q: Can you explain why your FX headwind guidance is less than implied by spot rates?
A: The primary FX headwind arises from the Russian ruble, contributing over 60% of the variance. We mitigate currency impacts through natural hedging with over 60% of our debt in euros, and additional hedging positions covering exposures to the yen and euro. This strategy reduces P&L volatility despite currency fluctuations. (Citations: ) -
New Market Contributions to HTU Growth
Q: Are new markets contributing to HTU growth in 2025?
A: Our 2025 guidance doesn't anticipate significant volume from new geographies. Growth is driven organically in existing markets like Japan and parts of Europe, despite some areas like Italy and the Czech Republic experiencing slower growth due to flavor bans. We remain hopeful for future market openings but haven't included them in our current projections. (Citations: )